Business Description
Balaxi Pharmaceuticals Ltd
ISIN : INE618N01022
Compare
Compare
Traded in other countries / regions
BALAXI.India IPO Date
2015-11-30Description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Geographically it earns key revenue from Guatemala.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.9 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 0.75 | |||||
| Interest Coverage | 25.44 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.65 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.3 | |||||
| 3-Year EBITDA Growth Rate | -49.9 | |||||
| 3-Year EPS without NRI Growth Rate | -14.7 | |||||
| 3-Year Book Growth Rate | 41.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.71 | |||||
| 9-Day RSI | 52.98 | |||||
| 14-Day RSI | 48.7 | |||||
| 3-1 Month Momentum % | -32.16 | |||||
| 6-1 Month Momentum % | -39.73 | |||||
| 12-1 Month Momentum % | -10.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.45 | |||||
| Quick Ratio | 2.22 | |||||
| Cash Ratio | 0.88 | |||||
| Days Inventory | 217.05 | |||||
| Days Sales Outstanding | 83.73 | |||||
| Days Payable | 77.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.9 | |||||
| Shareholder Yield % | -2.27 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.31 | |||||
| Operating Margin % | 17.77 | |||||
| Net Margin % | 13.5 | |||||
| FCF Margin % | 1.25 | |||||
| ROE % | 18.65 | |||||
| ROA % | 14.04 | |||||
| ROIC % | 25.06 | |||||
| 3-Year ROIIC % | -100.57 | |||||
| ROC (Joel Greenblatt) % | 31.05 | |||||
| ROCE % | 20.92 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.41 | |||||
| PE Ratio without NRI | 13.35 | |||||
| Shiller PE Ratio | 23.88 | |||||
| Price-to-Owner-Earnings | 210.3 | |||||
| PEG Ratio | 1.38 | |||||
| PS Ratio | 1.72 | |||||
| PB Ratio | 1.99 | |||||
| Price-to-Tangible-Book | 2.23 | |||||
| Price-to-Free-Cash-Flow | 132.14 | |||||
| Price-to-Operating-Cash-Flow | 89.49 | |||||
| EV-to-EBIT | 9.73 | |||||
| EV-to-EBITDA | 9.25 | |||||
| EV-to-Revenue | 1.51 | |||||
| EV-to-FCF | 121.17 | |||||
| Price-to-GF-Value | 0.95 | |||||
| Price-to-Projected-FCF | 3.14 | |||||
| Price-to-Graham-Number | 1.14 | |||||
| Price-to-Net-Current-Asset-Value | 2.53 | |||||
| Earnings Yield (Greenblatt) % | 10.28 | |||||
| FCF Yield % | 0.78 | |||||
| Forward Rate of Return (Yacktman) % | 8.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Balaxi Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 2,636.218 | ||
| EPS (TTM) (₹) | 6.796 | ||
| Beta | 0.94 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.19 | ||
| Volatility % | 55.56 | ||
| 14-Day RSI | 48.7 | ||
| 14-Day ATR (₹) | 3.267878 | ||
| 20-Day SMA (₹) | 81.2105 | ||
| 12-1 Month Momentum % | -10.69 | ||
| 52-Week Range (₹) | 74 - 151.45 | ||
| Shares Outstanding (Mil) | 50.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Balaxi Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Balaxi Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Balaxi Pharmaceuticals Ltd Frequently Asked Questions
What is Balaxi Pharmaceuticals Ltd(NSE:BALAXI)'s stock price today?
The current price of NSE:BALAXI is ₹83.11. The 52 week high of NSE:BALAXI is ₹151.45 and 52 week low is ₹74.00.
When is next earnings date of Balaxi Pharmaceuticals Ltd(NSE:BALAXI)?
The next earnings date of Balaxi Pharmaceuticals Ltd(NSE:BALAXI) is .
Does Balaxi Pharmaceuticals Ltd(NSE:BALAXI) pay dividends? If so, how much?
Balaxi Pharmaceuticals Ltd(NSE:BALAXI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers